VRDN
Live chart
What they do
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R.
For information only · Important disclosures
Grades vs sector
No sector grades for VRDN yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Held by 1 of 5 live models: Coteau Long Book.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.10 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-2.75 vs trailing $-3.39. Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Piotroski F-score 3/9 · last two fiscal years
Altman Z-score 1.5 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $70.8M | $-342.6M | $-276.9M |
| 2024 | $302.0K | $-269.9M | $-232.8M |
| 2023 | $314.0K | $-237.7M | $-185.1M |
| 2022 | $1.8M | $-129.9M | $-94.6M |
| 2021 | $3.0M | $-79.4M | $-54.9M |
| 2020 | $1.1M | $-110.7M | $-29.8M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +241.9%.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | -1.03 | -1.05 | -2.3% |
| 2026-05-05 | -1.08 | -0.90 | +16.3% |
| 2026-02-26 | -1.00 | -1.08 | -8.0% |
| 2025-11-05 | -0.94 | -0.34 | +63.9% |
| 2025-08-06 | -0.98 | -1.00 | -1.6% |
| 2025-05-06 | -0.96 | -0.87 | +9.8% |
| 2025-02-26 | -1.04 | -0.81 | +22.4% |
| 2024-11-12 | -1.05 | -1.15 | -9.5% |
Insider trades
$245.0K
$103.2K
–
Stats refreshed 2026-10-21 18:16:57 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026